$250 Million is the total value of VHCP Management II, LLC's 19 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 35.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVXS | AveXis Inc | $76,959,000 | -2.3% | 1,035,657 | 0.0% | 30.74% | -4.6% | |
| BHVN | New | Biohaven Pharmaceuticals | $37,930,000 | – | 1,664,300 | +100.0% | 15.15% | – |
| ASND | Buy | Ascendis Pharma A/S | $27,385,000 | +20.5% | 986,492 | +21.6% | 10.94% | +17.7% |
| EDGE | Edge Therapeutics Inc | $19,839,000 | +12.6% | 1,933,582 | 0.0% | 7.92% | +9.9% | |
| DBV Technologies | $18,935,000 | +1.3% | 373,617 | 0.0% | 7.56% | -1.1% | ||
| RARX | Buy | Ra Pharmaceuticals | $14,426,000 | -6.5% | 769,771 | +6.2% | 5.76% | -8.8% |
| BCRX | Sell | BioCryst Pharmaceuticals Inc | $13,762,000 | -73.0% | 2,475,167 | -59.2% | 5.50% | -73.7% |
| ARGX | New | Argenx | $13,615,000 | – | 647,015 | +100.0% | 5.44% | – |
| AXGT | Sell | Axovant Sciences Ltd | $6,997,000 | +9.0% | 301,718 | -29.8% | 2.80% | +6.4% |
| XLRN | Acceleron Pharma Inc | $4,768,000 | +14.8% | 156,880 | 0.0% | 1.90% | +12.1% | |
| CTMX | CytomX Therapeutics Inc | $4,478,000 | -10.3% | 288,915 | 0.0% | 1.79% | -12.4% | |
| ABIO | ARCA biopharma Inc | $2,589,000 | -5.9% | 1,078,932 | 0.0% | 1.03% | -8.2% | |
| AKTX | Buy | Akari Therapeutics Plc | $1,965,000 | -52.0% | 426,297 | +15.4% | 0.78% | -53.1% |
| KALV | Kalvista Pharmaceuticals | $1,631,000 | -0.2% | 221,651 | 0.0% | 0.65% | -2.7% | |
| LPCN | Sell | Lipocine Inc | $1,555,000 | -5.1% | 386,928 | -7.9% | 0.62% | -7.3% |
| OCRX | Ocera Therapeutics | $1,413,000 | -11.4% | 1,217,872 | 0.0% | 0.56% | -13.6% | |
| OBSV | New | Obseva SA | $1,283,000 | – | 150,000 | +100.0% | 0.51% | – |
| ADVM | Adverum Biotechnologies Inc | $700,000 | -7.4% | 280,000 | 0.0% | 0.28% | -9.4% | |
| SRRA | Sierra Oncology Inc | $153,000 | -23.5% | 130,798 | 0.0% | 0.06% | -25.6% | |
| ADHD | Exit | Alcobra Ltd | $0 | – | -185,140 | -100.0% | -0.09% | – |
| STML | Exit | Stemline Therapeutics Inc | $0 | – | -228,130 | -100.0% | -0.80% | – |
| CHRS | Exit | Coherus Biosciences Inc | $0 | – | -95,276 | -100.0% | -0.82% | – |
| BOLD | Exit | Audentes Therapeutics | $0 | – | -458,882 | -100.0% | -3.20% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Ascendis Pharma A/S | 16 | Q3 2019 | 18.3% |
| BioCryst Pharmaceuticals Inc | 15 | Q3 2019 | 20.9% |
| Ra Pharmaceuticals | 12 | Q3 2019 | 6.4% |
| Biohaven Pharmaceuticals | 11 | Q4 2019 | 18.1% |
| Obseva SA | 11 | Q4 2019 | 12.2% |
| DBV Technologies | 10 | Q1 2018 | 11.6% |
| Kalvista Pharmaceuticals | 10 | Q4 2019 | 6.4% |
| Bellerophon Therapeutics | 10 | Q4 2019 | 3.0% |
| AveXis Inc | 9 | Q1 2018 | 32.2% |
| Edge Therapeutics Inc | 9 | Q4 2017 | 18.2% |
View VHCP Management II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-10-26 |
| 4 | 2022-10-20 |
| 4 | 2022-10-17 |
| 4 | 2022-10-11 |
| 4 | 2022-10-06 |
| 4 | 2022-10-03 |
| 4 | 2022-09-28 |
| 4 | 2022-09-07 |
| 4 | 2022-09-01 |
| 4 | 2022-08-02 |
View VHCP Management II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.